Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel adjunctive therapy for seizures associated with Lennox-Gastaut syndrome
2014-002321-35Phase 3Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2017
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of perampanel in Lennox-Gastaut syndrome (LGS) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Median percent change in drop seizure frequency per 28 days. Started Apr 2017; status: terminated.
02
Drugs
perampanel
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2014-002321-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002321-35.